

AMENDMENTS IN THE CLAIMS

Please CANCEL claims 29-31.

Please AMEND claims 15, 18, 27, 33, 37, and 38 as follows.

D1  
15. (Amended) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one homologous DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, and a DNA sequence encoding a Dengue virus serotype 4 antigen.

D2  
18. (Amended) The recombinant MVA virus according to Claim 15, wherein the DNA sequences are inserted at the site of one or more naturally occurring deletions within the MVA virus genome.

D3  
27. (Amended) (Allowed) A composition comprising a first and second component, wherein the first component is a vector comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, or a DNA sequence encoding a Dengue virus serotype 4 antigen and wherein the more than one DNA sequences are under the transcriptional control of a T7 RNA polymerase promoter and the second component is a recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding T7 RNA polymerase.

D4  
33. (Amended) A recombinant Modified Vaccinia Ankara (MVA) virus comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 preM antigen, a DNA sequence encoding a Dengue virus serotype 2 preM antigen, a DNA sequence encoding a Dengue virus serotype 3 preM antigen, and a DNA sequence encoding a Dengue virus serotype 4 preM antigen.

D5  
37. (Amended) A recombinant Modified Vaccinia Ankara (MVA) virus comprising